\-\ Texto\\:\\ \ \(0\)\
\-\ hypertension\ \(298\)\
\-\ blood\\ pressure\\ control\ \(4\)\
\-\ multiple\\ lesions\\ involving\\ both\\ white\\ matter\\ and\\ cortex\\ involving\\ both\\ cerebral\\ hemispheres\\ and\\ cerebellum\\.\ \(0\)\
\-\ no\\ mass\\ effect\\ nor\\ enhancement\\ nor\\ restricted\\ diffusion\\.\ \(0\)\
\-\ posterior\\ reversible\\ encephalopathy\\ syndrome\\ \\(pres\\)\ \(0\)\
\-\ \\â\\€\\¢\\ cerebral\\ infarction\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ pres\ \(0\)\
\-\ 33\\ year\\ old\\ man\\ with\\ end\\ stage\\ renal\\ disease\\.\ \(1\)\
\-\ recent\\ decreased\\ level\\ of\\ consciousness\\.\ \(0\)\
\-\ pres\\ should\\ be\\ reversible\\ after\\ removing\\ the\\ inciting\\ factor\\ and\\ controlling\\ hypertension\\ \\(if\\ present\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pres\\:\\ 0\\.23490262395631878\ \(0\)\
\-\ reversible\\:\\ 0\\.14678143514379954\ \(0\)\
\-\ nor\\:\\ 0\\.11710315851069587\ \(0\)\
\-\ removing\\:\\ 0\\.09238564758374869\ \(0\)\
\-\ hypertension\\:\\ 0\\.08637900134103046\ \(0\)\
\-\ controlling\\:\\ 0\\.08484992111064459\ \(0\)\
\-\ inciting\\:\\ 0\\.08116168941254484\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.08035971033825065\ \(0\)\
\-\ involving\\:\\ 0\\.07688223753854599\ \(0\)\
\-\ cerebral\\:\\ 0\\.0759088846606172\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.06450421525702868\ \(0\)\
\-\ hemispheres\\:\\ 0\\.05836972496057927\ \(0\)\
\-\ 33\\:\\ 0\\.05683963832426431\ \(0\)\
\-\ both\\:\\ 0\\.05595384591502875\ \(0\)\
\-\ factor\\:\\ 0\\.05591245035529474\ \(0\)\
\-\ end\\:\\ 0\\.05561771294215758\ \(0\)\
\-\ consciousness\\:\\ 0\\.05561771294215758\ \(0\)\
\-\ cerebellum\\:\\ 0\\.054502182467931565\ \(0\)\
\-\ restricted\\:\\ 0\\.05041944232538625\ \(0\)\
\-\ control\\:\\ 0\\.04994278843767145\ \(0\)\
\-\ diffusion\\:\\ 0\\.04903956201522772\ \(0\)\
\-\ cortex\\:\\ 0\\.04687773236861499\ \(0\)\
\-\ stage\\:\\ 0\\.04673121062728649\ \(0\)\
\-\ infarction\\:\\ 0\\.04477574929266782\ \(0\)\
\-\ matter\\:\\ 0\\.04313435859488202\ \(0\)\
\-\ pressure\\:\\ 0\\.043024780895158196\ \(0\)\
\-\ effect\\:\\ 0\\.038789208372682626\ \(0\)\
\-\ recent\\:\\ 0\\.036829731395382016\ \(0\)\
\-\ white\\:\\ 0\\.036334669393743815\ \(0\)\
\-\ disease\\:\\ 0\\.03581378310809498\ \(0\)\
\-\ should\\:\\ 0\\.03492575053703589\ \(0\)\
\-\ renal\\:\\ 0\\.03291635319818037\ \(0\)\
\-\ decreased\\:\\ 0\\.032573800034930246\ \(0\)\
\-\ level\\:\\ 0\\.031575500354447845\ \(0\)\
\-\ syndrome\\:\\ 0\\.03133213559916207\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0313102389024293\ \(0\)\
\-\ blood\\:\\ 0\\.02990270605781153\ \(0\)\
\-\ if\\:\\ 0\\.029727479920264557\ \(0\)\
\-\ enhancement\\:\\ 0\\.029365240591320972\ \(0\)\
\-\ lesions\\:\\ 0\\.02932769879928138\ \(0\)\
\-\ metastatic\\:\\ 0\\.02757832568738577\ \(0\)\
\-\ man\\:\\ 0\\.02590938260371794\ \(0\)\
\-\ posterior\\:\\ 0\\.025251776265416005\ \(0\)\
\-\ present\\:\\ 0\\.024743701973483086\ \(0\)\
\-\ multiple\\:\\ 0\\.023074435942041907\ \(0\)\
\-\ after\\:\\ 0\\.022666682084733363\ \(0\)\
\-\ \\(\\:\\ 0\\.018522095544714373\ \(0\)\
\-\ \\)\\:\\ 0\\.018295838259315515\ \(0\)\
\-\ be\\:\\ 0\\.016894316965947807\ \(0\)\
\-\ mass\\:\\ 0\\.015236679576250826\ \(0\)\
\-\ year\\:\\ 0\\.012257759862473265\ \(0\)\
\-\ old\\:\\ 0\\.011217110216182751\ \(0\)\
\-\ no\\:\\ 0\\.011031335265433359\ \(0\)\
\-\ and\\:\\ 0\\.006923423297393018\ \(0\)\
\-\ \\.\\:\\ 0\\.0022756112882914275\ \(0\)\
\-\ the\\:\\ 0\\.0017724267269695615\ \(0\)\
\-\ with\\:\\ 0\\.001500053539613971\ \(0\)\
\-\ of\\:\\ 0\\.0014936384717690824\ \(0\)\
